NEX-22
Undisclosed oncology target
PreclinicalActive
Key Facts
About Nanexa AB
Nanexa AB leverages its innovative PharmaShell® technology to create long-acting injectable drug formulations, aiming to transform treatment paradigms by enhancing patient convenience and adherence. The company's lead program, NEX-20, is a long-acting version of azacitidine for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), currently in Phase 1 development. With a public listing and strategic collaborations, Nanexa is positioned to advance its pipeline and expand its platform applications across multiple therapeutic areas.
View full company profileTherapeutic Areas
Other Undisclosed oncology target Drugs
| Drug | Company | Phase |
|---|---|---|
| Internal Program 1 | AbCellera | Lead Optimization |
| UGN-302 | UroGen Pharma | Preclinical |
| BPI-002 | BeyondSpring | Preclinical |